SerenQ Retatrutide Pen

Every SerenQ product carries a unique serial number and a QR code printed on the label. Scan it with any phone camera and you can independently confirm the pen is genuine SerenQ stock and check its batch details before you open the carton.

One code per pen. Each one can only be registered once, so a duplicate scan is an immediate red flag.

Retatrutide is a synthetic, long-acting peptide agonist that binds three separate incretin receptors at once: the GLP-1 receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. That third receptor is what separates it from the previous generation of agonists in the class. Semaglutide targets GLP-1 alone. Tirzepatide targets GLP-1 and GIP together. Retatrutide adds glucagon on top, making it the first triple agonist to enter late stage clinical development.

Structurally it is a 39 amino acid peptide, engineered from a GIP backbone with substitutions and a fatty acid moiety attached via a linker for reversible albumin binding. That albumin binding is what carries the plasma half-life out to approximately 6 days, making weekly dosing the operating assumption in the published trials.

Each receptor pulls in a different direction in the research literature. GLP-1 activation drives glucose dependent insulin secretion, suppresses glucagon in the fed state, delays gastric emptying, and modulates hypothalamic satiety signalling. GIP activation adds a separate insulinotropic route via pancreatic beta cells and appears to influence adipose tissue metabolism. Glucagon receptor activation, counter-intuitive in a compound aimed at metabolic control, adds a thermogenic and lipolytic dimension via hepatic and adipose tissue signalling. In Phase II data published to date, the combined effect on body weight and adiposity has consistently outperformed both single and dual agonists tested in matched cohorts.

Research applications span glycaemic control, body weight and adiposity, appetite regulation, energy expenditure and hepatic lipid handling. Both the 20mg and 40mg pens deliver the same molecule at the same 300 unit graduation, so the only variable across the two is concentration per unit.

The pen format

Both strengths use the same pen platform. Instead of a lyophilised vial that has to be reconstituted with bacteriostatic water, calculated for concentration and drawn up with a syringe, the retatrutide arrives pre-dissolved in a stabilised solution and pre-loaded into a graduated injection pen with a dial and a dose window. Every dial setting delivers a consistent, verifiable volume.

20mg pen

• 20mg of retatrutide per pen, pre-dissolved in solution
• 1 unit = 66.7mcg
• 15 units on the dial gives 1mg
• 300 units in total, which works out at 20 full 15 unit draws per pen

40mg pen

• 40mg of retatrutide per pen, pre-dissolved in solution
• 1 unit = 133mcg
• 15 units on the dial gives 2mg
• 300 units in total, which works out at 20 full 15 unit draws per pen

Shared across both strengths

• Dial and dose window let you set the exact amount and read it back before dispensing
• 4 screw on pen tips supplied, individually sealed, 32G 0.23 x 4mm
• Protective cap, clip and a rigid retail carton for storage and transport
• Batch number, expiry and serial printed directly on the pen barrel, not just the box

Handling and storage

• Store refrigerated at 2 to 8°C. Do not freeze
• Keep in the outer carton, away from direct light
• Solution should be clear and colourless. Discard if cloudy, discoloured or if particulates are visible
• Short periods at room temperature during transit are expected and normal, though prolonged exposure will degrade potency
• Use a fresh sealed tip for each dispense and dispose of tips in a sharps container
• Expiry 12/2027 on sealed, correctly stored stock
• Keep out of reach of children and animals

What is in the box

• 1 × SerenQ Retatrutide pre-filled injection pen (20mg or 40mg per your selection above)
• 4 × sealed pen tips, 32G 0.23 x 4mm
• Serialised, QR coded retail carton